Skip to main
TYRA

Tyra Biosciences (TYRA) Stock Forecast & Price Target

Tyra Biosciences (TYRA) Analyst Ratings

Based on 9 analyst ratings
Strong Buy
Strong Buy 56%
Buy 44%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Tyra Biosciences is a promising company with a diverse product pipeline and a unique precision medicine platform, SNAP, which could drive success in the competitive biotechnology market. Market research and analyst predictions suggest strong potential for TYRA and dabogratinib, both of which have shown promising data in their respective indications and could generate significant peak sales. However, risks of delays and negative clinical data should be considered before investing in the company.

Bears say

Tyra Biosciences is a clinical-stage biotechnology company with a promising yet unproven precision medicine platform that targets Fibroblast Growth Factor Receptor (FGFR) biology. While the company's approach may offer potential for targeted treatments in various diseases, its current drug candidates have shown potential safety risks and may face significant competition in the market. Additionally, the company's financials suggest a need for additional funding in the near future, which adds risk to the valuation of the stock.

Tyra Biosciences (TYRA) has been analyzed by 9 analysts, with a consensus rating of Strong Buy. 56% of analysts recommend a Strong Buy, 44% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Tyra Biosciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Tyra Biosciences (TYRA) Forecast

Analysts have given Tyra Biosciences (TYRA) a Strong Buy based on their latest research and market trends.

According to 9 analysts, Tyra Biosciences (TYRA) has a Strong Buy consensus rating as of Jun 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $49.44, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $49.44, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Tyra Biosciences (TYRA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.